CommercialPrior AuthMedium impact
08.01.35j, Asparaginase Erwinia Chrysanthemi (recombinant)-rywn (Rylaze®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Aug 25, 2025
We identified it
Jun 19, 2026
Summary
This policy establishes new medical necessity criteria for Rylaze® (asparaginase Erwinia chrysanthemi recombinant-rywn), a specialized pharmacy agent used in acute lymphoblastic leukemia treatment. The billing team must implement prior authorization requirements and ensure claims meet the updated medical necessity standards outlined in this policy effective August 25, 2025.
Action Required
By August 25, 2025: Billing team must update claim submission procedures to require prior authorization for J9019 (asparaginase Erwinia chrysanthemi recombinant-rywn). Review the full policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=08&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-08-01-35j to identify specific medical necessity criteria. Update billing system rules to validate all J9019 claims against these criteria before submission. Notify providers and oncology staff of new documentation requirements. Ensure prior authorization is obtained before dispensing. Claims submitted without meeting medical necessity criteria will be denied.